Compare LITS & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITS | COHN |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 32.6M |
| IPO Year | 2003 | 2003 |
| Metric | LITS | COHN |
|---|---|---|
| Price | $0.86 | $8.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 256.5K | 7.2K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 10.27% |
| EPS Growth | 13.81 | ★ 5537.50 |
| EPS | 0.48 | ★ 1.47 |
| Revenue | N/A | ★ $275,564,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $1.75 | $6.51 |
| Revenue Growth | N/A | ★ 246.19 |
| 52 Week Low | $0.69 | $8.93 |
| 52 Week High | $2.00 | $32.60 |
| Indicator | LITS | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 37.83 |
| Support Level | $0.74 | $8.93 |
| Resistance Level | $1.08 | $10.71 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 15.74 | 14.08 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.